Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Enhertu
Pharma
Daiichi enlists Alteogen for subcutaneous Enhertu in $300M deal
Alteogen will use its human hyaluronidase hybridization platform to develop the subcutaneous formulation.
Zoey Becker
Nov 8, 2024 11:19am
Daiichi, Fosun, Yuhan and more—Fierce Pharma Asia
Sep 27, 2024 10:15am
Daiichi, Eisai, Granules—Fierce Pharma Asia
Sep 20, 2024 10:16am
Daiichi, AZ kick off first Enhertu DTC campaign
Sep 19, 2024 7:00pm
AZ, Daiichi's Enhertu helps patients with brain metastases
Sep 13, 2024 11:04am
AZ, Daiichi's Enhertu turned away by NICE on pricing grounds
Jul 29, 2024 9:16am
